Successful reintroduction of statin therapy after myositis: was there another cause?
Rando
Leo P
LP
Endocrinology Unit, and Monash University Department of Medicine, Box Hill Hospital, Box Hill, VIC, Australia.
Cording
Sarah A L
SA
Newnham
Harvey H
HH
D000328:Adult; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000069059:Atorvastatin; D006538:Heptanoic Acids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D007037:Hypothyroidism / Q000150:complications*; D008297:Male; D009220:Myositis / Q000139:chemically induced / Q000209:etiology*; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use; D019821:Simvastatin / Q000009:adverse effects / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin